As of 2024, the global Central Nervous System (CNS) Stimulant Drugs Market is valued at USD 12.9 billion, and is projected to reach USD 17.8 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.6% during the forecast period (2025–2032). This growth is driven by the increasing prevalence of ADHD among children and adults, rising diagnoses of narcolepsy, and the expanding off-labe..